Skip to content
Menu

Pharvaris N.V. PHVS

Full chart Compare
Set alert

Price alert · PHVS

All alert types
31.43 USD -0.23 (-0.73%)

As ofNov 20, 2026, 3:25 PM EST

30.43 Day range 31.99
23.15 52-week range 43.25
YTD
+13.26%
1 year
+29.88%

 

No chart data for this range yet.
Market cap
2.22B
EPS (ttm)
-3.13
Shares out
70.79M
Forward P/E
-10.51
YTD return
+13.26%
1-year return
+29.88%
50-day average
32.95
200-day average
31.41
Enterprise value
1.95B
Price / book
7.53
Volume
318.73K
Avg volume
757.01K
Open
31.19
Previous close
31.66
Day's range
30.43 – 31.99
52-week range
23.15 – 43.25
Beta
-2.52
Analysts
Strong Buy
Price target
58.19 (+85.1%)
Earnings date
Apr 1, 2027

Key statistics

Free cash flow
-96.46M
Total cash
282.73M
Total debt
603.93K
Return on equity
-62.78%
Short % of float
4.35%

Fundamental scorecard

1 of 25 checks passed on PHVS’s reported financials

ValueGrowthProfitabilityHealthDividend

1of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health No data
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
PHVS Revenue — quarterly 0
PHVS Net income — quarterly -47.41M
PHVS EPS — quarterly -0.67

Earnings

PHVS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Apr 1, 2027Mar 30, 2027-0.81———
Nov 12, 2026Sep 30, 2026-0.8134-0.77+0.04+5.34%
Aug 12, 2026Jun 30, 2026-0.7467-0.81-0.06-8.48%
May 12, 2026Mar 31, 2026-0.82187-0.70+0.12+14.83%
Apr 2, 2026Dec 31, 2025-0.71462-0.84565-0.13-18.34%
Nov 12, 2025Sep 30, 2025-0.78-0.70+0.08+10.26%

Upgrades / downgrades

PHVS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 23, 2026B of A SecuritiesupNeutralBuy
Sep 10, 2026GuggenheimmainBuyBuy
Sep 9, 2026Morgan StanleymainOverweightOverweight
Sep 9, 2026Leerink PartnersmainOutperformOutperform
Sep 9, 2026Wells FargomainOverweightOverweight
Sep 9, 2026RBC CapitalmainOutperformOutperform

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Sector
Healthcare
Industry
Biotechnology
Country
Switzerland

News

Your note

Sign in to keep a note on PHVS — it syncs with the Stock Master app.

Insider holders

PHVS insider holders
InsiderRelationLatest transactionDateShares held
ABELE STEFANChief Operating OfficerConversion of Exercise of derivative securitySep 14, 202639,068
BJORK ELISABETHDirectorConversion of Exercise of derivative securitySep 16, 202615,167
GLASSMAN ROBERT R.DirectorConversion of Exercise of derivative securitySep 16, 202610,500
LESAGE ANNE SIMONNE J PH.D.OfficerSaleSep 16, 20260
LU PENGPresidentConversion of Exercise of derivative securitySep 21, 2026110,261
MODIG BERNDT B.A.EChief Executive OfficerConversion of Exercise of derivative securitySep 16, 20260

Institution ownership

PHVS institution ownership
Holder% heldSharesValueReported
FMR, LLC10.58%6,921,820219.14MSep 29, 2026
Wellington Management Group, LLP10.24%6,696,804212.02MSep 29, 2026
Foresite Capital Management IV, LLC7.31%4,778,581151.29MSep 29, 2026
venBio Partners LLC6.82%4,458,977141.17MSep 29, 2026
Eqt Fund Management S.a R.l.5.24%3,424,609108.42MSep 29, 2026
Viking Global Investors, L.P.4.48%2,933,31092.87MSep 29, 2026

Fund ownership

PHVS fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.10%1,373,19343.48MSep 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.78%1,165,41436.90MJul 30, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.22%800,00025.33MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund0.99%644,59120.41MAug 30, 2026
Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund0.61%400,00012.66MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.61%399,47912.65MSep 29, 2026